204 related articles for article (PubMed ID: 19100593)
1. Mousepox in the C57BL/6 strain provides an improved model for evaluating anti-poxvirus therapies.
Parker S; Siddiqui AM; Oberle C; Hembrador E; Lanier R; Painter G; Robertson A; Buller RM
Virology; 2009 Mar; 385(1):11-21. PubMed ID: 19100593
[TBL] [Abstract][Full Text] [Related]
2. Co-administration of the broad-spectrum antiviral, brincidofovir (CMX001), with smallpox vaccine does not compromise vaccine protection in mice challenged with ectromelia virus.
Parker S; Crump R; Foster S; Hartzler H; Hembrador E; Lanier ER; Painter G; Schriewer J; Trost LC; Buller RM
Antiviral Res; 2014 Nov; 111():42-52. PubMed ID: 25128688
[TBL] [Abstract][Full Text] [Related]
3. Using biomarkers to stage disease progression in a lethal mousepox model treated with CMX001.
Parker S; Schriewer J; Oberle C; Robertson A; Lanier R; Painter G; Buller RM
Antivir Ther; 2008; 13(7):863-73. PubMed ID: 19043920
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of disease and viral biomarkers as triggers for therapeutic intervention in respiratory mousepox - an animal model of smallpox.
Parker S; Chen NG; Foster S; Hartzler H; Hembrador E; Hruby D; Jordan R; Lanier R; Painter G; Painter W; Sagartz JE; Schriewer J; Mark Buller R
Antiviral Res; 2012 Apr; 94(1):44-53. PubMed ID: 22381921
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of cidofovir treatment of mice infected with ectromelia (mousepox) virus encoding interleukin-4.
Robbins SJ; Jackson RJ; Fenner F; Beaton S; Medveczky J; Ramshaw IA; Ramsay AJ
Antiviral Res; 2005 Apr; 66(1):1-7. PubMed ID: 15781125
[TBL] [Abstract][Full Text] [Related]
6. Buccal viral DNA as a trigger for brincidofovir therapy in the mousepox model of smallpox.
Crump R; Korom M; Buller RM; Parker S
Antiviral Res; 2017 Mar; 139():112-116. PubMed ID: 28039021
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of therapeutic intervention with an oral ether-lipid analogue of cidofovir (CMX001) in a lethal mousepox model.
Parker S; Touchette E; Oberle C; Almond M; Robertson A; Trost LC; Lampert B; Painter G; Buller RM
Antiviral Res; 2008 Jan; 77(1):39-49. PubMed ID: 17904231
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model.
Buller RM; Owens G; Schriewer J; Melman L; Beadle JR; Hostetler KY
Virology; 2004 Jan; 318(2):474-81. PubMed ID: 14972516
[TBL] [Abstract][Full Text] [Related]
9. The Pathogenesis and Immunobiology of Mousepox.
Sigal LJ
Adv Immunol; 2016; 129():251-76. PubMed ID: 26791861
[TBL] [Abstract][Full Text] [Related]
10. A single cidofovir treatment rescues animals at progressive stages of lethal orthopoxvirus disease.
Israely T; Paran N; Lustig S; Erez N; Politi B; Shafferman A; Melamed S
Virol J; 2012 Jun; 9():119. PubMed ID: 22709563
[TBL] [Abstract][Full Text] [Related]
11. A mouse model of lethal infection for evaluating prophylactics and therapeutics against Monkeypox virus.
Stabenow J; Buller RM; Schriewer J; West C; Sagartz JE; Parker S
J Virol; 2010 Apr; 84(8):3909-20. PubMed ID: 20130052
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Taterapox Virus in Small Animals.
Parker S; Crump R; Hartzler H; Buller RM
Viruses; 2017 Aug; 9(8):. PubMed ID: 28763036
[TBL] [Abstract][Full Text] [Related]
13. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge.
Yang G; Pevear DC; Davies MH; Collett MS; Bailey T; Rippen S; Barone L; Burns C; Rhodes G; Tohan S; Huggins JW; Baker RO; Buller RL; Touchette E; Waller K; Schriewer J; Neyts J; DeClercq E; Jones K; Hruby D; Jordan R
J Virol; 2005 Oct; 79(20):13139-49. PubMed ID: 16189015
[TBL] [Abstract][Full Text] [Related]
14. Ectromelia virus: the causative agent of mousepox.
Esteban DJ; Buller RML
J Gen Virol; 2005 Oct; 86(Pt 10):2645-2659. PubMed ID: 16186218
[TBL] [Abstract][Full Text] [Related]
15. Rapid expansion of CD8+ T cells in wild-type and type I interferon receptor-deficient mice correlates with protection after low-dose emergency immunization with modified vaccinia virus Ankara.
Volz A; Langenmayer M; Jany S; Kalinke U; Sutter G
J Virol; 2014 Sep; 88(18):10946-57. PubMed ID: 25008931
[TBL] [Abstract][Full Text] [Related]
16. A human recombinant analogue to plasma-derived vaccinia immunoglobulin prophylactically and therapeutically protects against lethal orthopoxvirus challenge.
Parker S; D'Angelo J; Buller RM; Smee DF; Lantto J; Nielsen H; Jensen A; Prichard M; George SL
Antiviral Res; 2021 Nov; 195():105179. PubMed ID: 34530009
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of CMX001 as a post exposure antiviral in New Zealand White rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans.
Rice AD; Adams MM; Wallace G; Burrage AM; Lindsey SF; Smith AJ; Swetnam D; Manning BR; Gray SA; Lampert B; Foster S; Lanier R; Robertson A; Painter G; Moyer RW
Viruses; 2011 Jan; 3(1):47-62. PubMed ID: 21373379
[TBL] [Abstract][Full Text] [Related]
18. Chronic Lymphocytic Choriomeningitis Infection Causes Susceptibility to Mousepox and Impairs Natural Killer Cell Maturation and Function.
Alves-Peixoto P; FĂ©rez M; Knudson CJ; Stotesbury C; Melo-Silva CR; Wong EB; Correia-Neves M; Sigal LJ
J Virol; 2020 Feb; 94(5):. PubMed ID: 31776282
[TBL] [Abstract][Full Text] [Related]
19. Redundant Function of Plasmacytoid and Conventional Dendritic Cells Is Required To Survive a Natural Virus Infection.
Kaminsky LW; Sei JJ; Parekh NJ; Davies ML; Reider IE; Krouse TE; Norbury CC
J Virol; 2015 Oct; 89(19):9974-85. PubMed ID: 26202250
[TBL] [Abstract][Full Text] [Related]
20. Mousepox in inbred mice innately resistant or susceptible to lethal infection with ectromelia virus. I. Clinical responses.
Bhatt PN; Jacoby RO
Lab Anim Sci; 1987 Feb; 37(1):11-5. PubMed ID: 3035273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]